Optilite® - Optimised Protein System

In this study, special protein assays were analyzed on the Roche cobas and Binding Site Optilite® platforms. The workflow, efficiency, and financial implications of the standalone Optilite® were compared to the automated cobas system, highlighting differences in performance and resource requirements.

The Optilite® analyzer from Binding Site offers a unique menu with over 50 assays, three methods for antigen excess detection, fully automated dilutions to end result, compact design, fast throughput, and simplified workflow for special protein testing. Faye Sims, Senior Biomedical Researcher at Peterborough City hospital, UK, provides a testimonial for why they use the Optilite analyzer in their laboratory. She highlights how using the Optilite allows them to run Freelite® assays more often and ensure the clinicians have the results in a timely manner to aid patient care.

Monday, November 17, at 16:00 GMT | 17:00 CET | 11:00 EST | 8:00 PST

Multiple myeloma (MM) is among the cancers having the longest delay from first symptoms to diagnosis. Patients often initially present to their primary care providers (PCPs) and may visit multiple times before being referred to a specialist. Laboratory testing is pivotal in the diagnostic workup, especially in primary care settings where initial investigations often occur.

The College of American Pathologists (CAP) has published guidelines for the laboratory detection and initial diagnosis of monoclonal gammopathies in 2022. Timely diagnosis has been proven to result in fewer complications and improved patient outcomes. Despite significant advancement in the understanding of MM biology and clear guidelines around diagnostic testing, the status of US PCPs’ understanding of MM diagnostic testing practices remain understudied.

This webinar will share the key findings of a national survey of US PCPs, the first of its kind, assessing the awareness of recommended MM diagnostic workup as well as the current approach to MM diagnosis among US PCPs. We will identify opportunities to improve laboratory test ordering practices and enhance patient care.

Join us to advance your understanding and approach to MM diagnosis.

Key learning objectives:

• Understand the importance of timely and guideline-compliant testing for MM and related plasma cell disorders.
• Assess the current knowledge and practices of US primary care providers (PCPs) regarding MM diagnostic testing and diagnosis.
• Explore how US PCPs are utilizing laboratory services and identify additional support needed to improve testing and patient care.
• Learn practical steps and frameworks to enhance guideline-compliant MM laboratory test ordering practices.

Who should attend?

Laboratory professionals, laboratory directors/decision makers, medical directors, primary care providers, and hematologists/oncologists.

Accreditation statement

SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

Binding Site introduces the Optilite® special protein analyzer, emphasizing its ability to enhance efficiency by saving time and reducing costs. The reliable and compact Optilite system features fully automated dilutions plus unrestricted access for samples and reagents, enabling a streamlined workflow. Unnecessary reagent waste is avoided with wide measuring ranges, large dilution steps, on-board cooling and long open-vial reagent stability. The Optilite offers three unique methods of antigen excess detection and achieves an average throughput of 120 tests per hour regardless of assay mix.

Antigen excess, also known as 'prozone' or 'hook effect', occurs when antigen levels are so high that they hinder antigen-antibody crosslinking. This leads to the formation of smaller immune complexes, causing immunoassays to underestimate high protein concentrations. Binding Site highlights the Optilite® Analyzer and how its software can utilize one of three different antigen excess detection methods when required during assay design. The Optilite features optimized antigen excess protection, preventing falsely low or false negative results and is a reliable and efficient solution for diagnostic testing.

Multiple myeloma is a blood cancer that develops in plasma cells in the bone marrow. Binding Site details how it is working with partners to raise awareness of multiple myeloma, and highlights how early recognition of the symptoms and confirmation of the diagnosis, and early referrals to hematologists and cancer care have the potential to improve the overall survival and quality of life for patients.

Lupus is an incurable immune system illness which can affect any part of the body. A butterfly-shaped rash across the cheeks and nose is a tell-tale sign of Lupus.

Lupus is an incurable immune system illness which can affect any part of the body. In lupus patients, major damage to the brain, kidneys, lungs, heart and skin is common.

Transforming monoclonal gammopathy management to address an unmet clinical need through an innovative mass spectrometry solution

Visit Binding Site at stand #8 or attend workshop on June 13

Discover our latest clinical content